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Edited by Lukas HuberAbstract R-spondins are a new group of Wnt/b-catenin signal-
ing agonists, however, the role of these proteins in bone remains
unclear. We reported herein that R-sponin1 (Rspo1) acted syner-
gistically with Wnt3A to activate Wnt/b-catenin signaling in the
uncommitted mesenchymal C2C12 cells. Furthermore, we found
that Rspo1 at concentrations as low as 10ng/ml synergized
strongly with Wnt3A to induce C2C12 osteoblastic diﬀerentia-
tion and osteoprotegerin expression. These events were blocked
by Wnt/b-catenin signaling antagonist Dickkopf-1. Finally, we
demonstrated that Rspo1 synergized with Wnt3A to induce pri-
mary mouse osteoblast diﬀerentiation. Together, these ﬁndings
suggest that Rpos1 may play an important role in bone remodel-
ing.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Studies in the past several years have established that Wnt/b-
catenin signaling plays a critical role in the regulation of bone
mass and is involved in many disorders of bone [1]. Osteoblast
diﬀerentiation is the primary event of bone formation, exem-
pliﬁed by the synthesis, deposition, and mineralization of the
extracellular matrix. One of the mechanisms whereby Wnt/b-
catenin signaling increases bone formation is via stimulation
of the development of osteoblasts [1]. Furthermore, Wnt/b-
catenin signaling in osteoblasts is able to coordinate postnatal
bone acquisition by controlling the diﬀerentiation and activity
of osteoclasts [2–6]. Osteoprotegerin (OPG) is a direct target
gene of the b-catenin–T-cell factor (TCF) complex in osteo-
blasts [5,7], and acts as a decoy receptor blocking the binding
of receptor activator of NF-kappaB ligand (RANKL) to its
cognate signaling receptor RANK on hematopoietic cells,
thereby inhibiting osteoclast formation as well as activity.Abbreviations: ALP, alkaline phosphatase; CM, conditioned medium;
Dkk1, Dickkopf-1; LRP6, low density lipoprotein receptor-related
protein 6; OCN, osteocalcin; OPG, osteoprotegerin; Rspo1, R-spondin
1; RANKL, receptor activator of NF-kappaB ligand
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doi:10.1016/j.febslet.2008.01.035R-spondins have been recently identiﬁed as a new group of
Wnt/b-catenin signaling agonists [8]. There are four members
in this group in human and mouse. R-spondin1 (Rspo1) has
been identiﬁed as a potent and speciﬁc mitogen for the gastro-
intestinal epithelium [9,10]. In addition, human Rspo1 is the
gene disrupted in a recessive syndrome characterized by XX
sex reversal, palmoplantar hyperkeratosis, and predisposition
to squamous cell carcinoma of the skin [11]. Although Wnt/
b-catenin signaling is critical for bone development and
remodeling, the role of R-spondins in bone is unclear. In the
present study, we have utilized the uncommitted mesenchymal
C2C12 cells and primary mouse osteoblasts to examine the
contribution of Wnt/b-catenin signaling to osteoblast diﬀeren-
tiation and OPG expression induced by human Rspo1.2. Materials and methods
2.1. Materials
HumanRspo1 plasmid pcMV6-XL5-hRspo1 was obtained fromOri-
Gene Technologies, Inc. Plasmid pGST-E-cadherin was provided by
Dr. Gail Johnson (University of Alabama at Birmingham, Alabama).
The Wnt signaling reporter construct TOPFLASH was from Upstate
Biotechnology. A b-galactosidase-expressing vector was from Prome-
ga. The preparation of human recombinant Rspo1 protein has been de-
scribed before [9]. Human recombinant Dkk1 protein and monoclonal
anti-OPG were obtained from R&D Systems. Monoclonal anti-phos-
phorylated-LRP6 was purchased from Cell Signaling Technology.
Monoclonal anti-b-catenin and anti-actin were obtained from BD Bio-
sciences and Sigma, respectively. Peroxidase labeled anti-mouse anti-
body and ECL system were purchased from Amersham Life Science.
The dual luciferase and b-galactosidase assay systems were from Pro-
mega. Alkaline phosphatase (ALP) assay kit was from Pierce. RNA-
Bee was from Tel-Test. The ProSTARTM Ultro HF RT-PCR Kit
was obtained from Strategene. All tissue culture media, serum, and
plastic-ware were obtained from Life Technologies Inc. Immobilon-P
transfer membrane was purchased from Millipore. Rainbow molecular
weight markers were purchased from GE Healthcare. Proteinase inhib-
itor cocktail Complete was obtained from Boehringer Mannheim.
2.2. Cell culture and conditioned media
Primary osteoblasts were isolated from calvariae of newborn mice as
described before [12]. The procedures involving mice are conducted in
accord with standards of humane animal care. Isolated osteoblasts
were cultured in minimal essential medium a-modiﬁcation containing
10% heat-inactivated fetal bovine serum. C2C12 cells, HEK293 cells,
Wnt3A-secreting L cells, Wnt5A-secreting L cells, and control L cells
were obtained from American Type Culture Collection. Wnt3A-secret-
ing L cells and Wnt5A-secreting L cells were cultured in Dulbeccos
minimum essential medium containing 10% of fetal bovine serum,
2 mM of L-glutamine, 100 U/ml of penicillin, 100 lg/ml of streptomy-
cin, and 350 lg/ml of G418. HEK293 cells and C2C12 cells wereblished by Elsevier B.V. All rights reserved.
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tioned medium (CM), Wnt5A CM, and L cell control CM were pre-
pared according to the manufacturers speciﬁcations. For Rspo1 CM
and control CM, HEK293 cells were cultured in 10 cm dishes, and
transiently transfected with pcMV6-XL5-hRspo1 or a control vector.
The media were changed with fresh Dulbeccos minimum essential
medium containing 10% fetal bovine serum 24 h after transfection.
After further 48 h incubation, the media were collected, centrifuged
to remove cell debris, and stored at 80 C.
2.3. Luciferase reporter assay
C2C12 cells were plated into 12-well plates. After overnight culture,
the cells were transiently transfected with 0.2 lg of the Wnt signaling
reporter construct TOPFLASH, and 0.2 lg of b-galactosidase-express-
ing vector. After 24 h incubation, cells were treated Rspo1 and/or
Wnt3A CM. Cells were then lysed 24 h later and both luciferase and
b-galactosidase activities were determined. The luciferase activity was
normalized to the b-galactosidase activity.2.4. Western blotting
Cells in 6-well plates were lysed in 0.5 ml of lysis buﬀer (phosphate-
buﬀered saline containing 1% Triton X-100 and 1 mM phenylmethyl-
sulfonyl ﬂuoride) at 4 C for 30 min. Equal quantities of protein were
subjected to SDS–PAGE under reducing conditions. Following trans-
fer to immobilon-P transfer membrane, successive incubations with
anti-b-catenin, anti-OPG, anti-LRP6, or anti-actin, and horseradish
peroxidase-conjugated secondary antibody were carried out for 60–Fig. 1. Rspo1 acts synergistically with Wnt3A to stabilize cytosolic free b
stabilization induced by Rspo1. C2C12 cells in 6-well plates were incubated
total cellular b-catenin were then analyzed by Western blotting as described
free b-catenin induced by Rspo1. In (B), C2C12 cells were treated with Rspo1
protein for 4 h. (D) Concentration dependent stabilization of cytosolic free b
for 2 h. (E,F), Rspo1 and Wnt3A synergistically induced stabilization of cyt
Rspo1 and/or 0.2% of Wnt3A CM for 4 h. In (F), C2C12 cells were treated wi
for each Western blotting were also probed with anti-actin antibody to verif120 min at room temperature. The immunoreactive proteins were then
detected using the ECL system. Films showing immunoreactive bands
were scanned by Kodak Digital Science DC120 Zoom Digital Camera.
2.5. GST-E-cadherin binding assay
The GST-E-cadherin binding assay was carried out exactly as de-
scribed in [13,14]. Uncomplexed b-catenin present in 100 lg of total
cell lysate was subjected to SDS–PAGE and detected using the mono-
clonal antibody to b-catenin.
2.6. Measurement of ALP activity
C2C12 cells in 12-well plates or primary mouse osteoblasts in 24-well
plates were treated for indicated amounts of various reagents indicated
in each ﬁgure legend. Cells were harvested for assay of ALP activity by
determining the amount of p-nitrophenol synthesized from p-nitrophe-
nylphosphate after 30 min of incubation at room temperature as de-
scribed in [15]. Cell lysates were analyzed for protein concentrations
using a Bio-Rad protein assay kit, and ALP activity was normalized
for total protein content in each well.
2.7. RT-PCR and real-time RT-PCR
Total RNA was isolated from cell cultures using RNA-Bee, and ﬁrst-
strand cDNA synthesis was performed using ProSTARTM Ultro HF
RT-PCR Kit primed with oligo(dT) primer in a 20 ll reaction mixture
containing 1 lg total RNA. For analysis of Rspo1 expression, the PCR
was carried out using 1 ll of cDNA in a total volume of 25 ll over 40
cycles of denaturing step at 94 C for 40 s, annealing at 60 C for 30 s-catenin in C2C12 cells. (A) Time course of cytosolic free b-catenin
with 2% of Rspo1 CM for 0–12 h, and the levels of cytosolic free and
in Section 2. (B,C) Concentration dependent stabilization of cytosolic
CM for 4 h. In (C), C2C12 cells were treated with recombinant Rspo1
-catenin induced by Wnt3A. C2C12 cells were treated with Wnt3A CM
osolic free b-catenin. In (E), C2C12 cells were treated with 10 ng/ml of
th 10 ng/ml of Rspo1 and/or 1% of Wnt3A CM for 4 h. All the samples
y equal loading.
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mouse Rspo1 are 5 0-GGCTGTGAGCTCTGTTCAGAAG-30 (+609
to +630) and 5 0-CCGGAAACCGCACAGCTTCCT-3 0 (+969 to
+989), respectively. The PCR product (381 bp) was loaded onto a
1.5% agarose gel and stained with ethidium bromide. For analysis of
osteocalcin (OCN) expression, real-time RT-PCRwas performed as de-
scribed in [16].3. Results
Recent studies reveal that Wnt/b-catenin signaling plays a
substantial role in the control of bone metabolism [1]. Rspo1
has been shown to be capable of activating Wnt/b-catenin
signaling [9,17,18]. We employed C2C12 cells to examine the
eﬀects of Rspo1 on Wnt/b-catenin signaling in osteoblasts.
C2C12 cells are uncommitted mesenchymal progenitor cells
that can be diﬀerentiated into osteoblasts upon the activation
of Wnt/b-catenin signaling [19]. Uncomplexed cytosolic b-cate-
nin (free b-catenin) is an active form of b-catenin and can enter
the cell nucleus and associate with the transcription factors
of the T-cell factor/lymphoid enhancing factor family, leading
to the transcription of Wnt target genes [13,14,20]. We exam-
ined cytosolic free b-catenin levels with GST-E-cadherin pull-
down assay to monitor Wnt/b-catenin signaling after Rspo1Fig. 2. Rspo1 acts synergistically with Wnt3A to activate Wnt
signaling in C2C12 cells. C2C12 cells in 12-well plates were transiently
transfected with 0.2 lg of the TOPFLASH luciferase construct and
0.2 lg of the b-galactosidase-expressing vector in each well. After 24 h
incubation, cells were treated with Rspo1 (10 ng/ml) and/or Wnt3A
CM. The luciferase activity was then measured 24 h later as described
in Section 2. In (A), 0.2% of Wnt3A CM was used. In (B), 1% of
Wnt3A CM was used. Values are the average of triple determinations
with the S.D. indicated by error bars.treatment. As shown in Fig. 1A, Rspo1 induced the stabiliza-
tion of cytosolic free b-catenin in a time-dependent manner.
After 4 h treatment with 2% of Rspo1 CM, the level of cyto-
solic free b-catenin in C2C12 cells was signiﬁcantly increased.
Furthermore, C2C12 cells were very sensitive to Rspo1 treat-
ment. Rspo1 induced the stabilization of cytosolic free b-cate-
nin in a dose-dependent manner to about 1% of Rspo1 CM or
10 ng/ml of recombinant Rspo1 protein. However, higher
doses of Rspo1 did not further increase the levels of cytosolic
free b-catenin (Fig. 1B and C). In contrast to Rspo1, Wnt3A
induced the stabilization of cytosolic free b-catenin in a
dose-dependent manner up to 25% of Wnt3A CM (Fig. 1D).
Importantly, Rspo1 and Wnt3A at low concentrations acted
synergistically to stabilize cytosolic free b-catenin in C2C12
cells (Fig. 1E and F).
To further characterize Rspo1-induced Wnt/b-catenin sig-
naling, C2C12 cells were transiently transfected with the
Wnt/b-catenin signaling reporter construct TOPFLASH. As
shown in Fig. 2, treatment of C2C12 cells with Rspo1 alone
at the concentration of 10 ng/ml resulted in an 2–3-fold in-
crease in TOPFLASH luciferase activity, and that treatment
of C2C12 cells with 0.2% or 1% of Wnt3A CM alone resulted
in 1.4-fold and 8-fold increases, respectively. However, when
treated with 10 ng/nl of recombinant Rspo1 protein plus
0.2% or 1% of Wnt3A CM, C2C12 cells displayed 11.7-fold
and 36.8-fold increases in TOPFLASH luciferase activity,
respectively. Together, these results indicate that Rspo1 at
low concentrations synergized strongly with Wnt3A to activate
Wnt/b-catenin signaling in C2C12 cells.
Wnt3A can induce osteoblast diﬀerentiation through a
mechanism involving the activation of Wnt/b-catenin signaling
[1,15,19]. To determine whether Rspo1 is also able to induce
osteoblastic diﬀerentiation, we examined the ALP activity in
C2C12 cells. ALP is a commonly used marker of osteoblast
diﬀerentiation. As shown in Fig. 3A, only small amounts of
ALP were detectable in C2C12 cells without Wnt stimulation.
Treatment of C2C12 cells with Wnt3A, but not Rspo1, for
2 days greatly induced them to produce ALP. For example,
treatment of C2C12 cells with 1250 ng/ml of recombinant
Rsp1 protein or 25% of Rspo1 CM resulted in only 2–3-fold
increases in ALP activity, while treatment with 25% of Wnt3A
CM resulted in an 17-fold increase in ALP activity (Fig. 3A
and B).
As we have demonstrated that Rspo1 at low concentrations
synergized strongly with Wnt3A to activate Wnt/b-catenin sig-
naling in C2C12 cells (Fig. 2), we then tested whether Rspo1
acts with Wnt3A to induce ALP production. As shown in
Fig. 3C and D, Rspo1 at low concentrations was able to syn-
ergize strongly with Wnt3A to promote C2C12 osteoblastic
diﬀerentiation. Treatment of C2C12 cells with 10 ng/ml of re-
combinant Rspo1 protein, 0.2% of Wnt3A CM or 1% of
Wnt3A CM resulted in 1–3-fold increases in ALP activity,
while treatment of C2C12 cells with 10 ng/ml of recombinant
Rspo1 protein plus 0.2% or 1% of Wnt3A CM resulted in
9.5-fold and 17-fold increases in ALP activity, respectively
(Fig. 3C).
To conﬁrm the eﬀect of Rspo1 on C2C12 osteoblastic diﬀer-
entiation, we examined expression of OCN, another com-
monly used marker of osteoblast diﬀerentiation. As shown in
Fig. 4, treatment with recombinant Rspo1 protein (10 ng/ml)
plus Wnt3A CM (1%) led to a signiﬁcant increase of OCN
expression in C2C12 cells.
Fig. 3. Rspo1 acts synergistically with Wnt3A to induce C2C12 ALP production in C2C12 cells. (A) ALP activity in C2C12 cells was induced by
Wnt3A CM and Rspo1 CM. C2C12 cells in 12-plates were incubated with 25% of L cell control CM, Wnt3A CM, Wnt5A CM, or Rspo1 CM at the
indicated concentrations. Cells were harvested 48 h later for ALP activity assay as described in Section 2. (B) ALP activity in C2C12 cells was induced
by recombinant Rspo1 protein. (C,D) Rspo1 acts synergistically with Wnt3A to induce C2C12 ALP production. In (C), recombinant Rspo1 protein
(10 ng/ml) and Wnt3A CM (0.2% or 1%) were used. In (D), Rspo1 CM (1–4%) and Wnt3A CM (1%) were used. All the values are the average of
triple determinations with the S.D. indicated by error bars.
Fig. 4. Rspo1 acts synergistically with Wnt3A to induce OCN
expression in C2C12 cells. C2C12 cells in 6-well plates were incubated
with recombinant Rspo1 protein (10 ng/ml), Wnt3A CM (1%), or
Rspo1 plus Wnt3A CM for 4 days, and the media were changed every
2 days. At the end of treatment, cells were harvested and OCN mRNA
was determined by real-time RT-PCR and normalized to the message
levels of b-actin mRNA. All the values are the average of triple
determinations with the S.D. indicated by error bars. *P < 0.05
indicates a signiﬁcant diﬀerence compared with cells incubated with
Rspo1, Wnt3A CM, or L cell control CM alone.
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(Fig. 5A). To conﬁrm the role of Rspo1 in osteoblast diﬀeren-
tiation, we treated primary mouse osteoblasts with Rspo1 in
the presence or absence of Wnt3A CM. While recombinant
Rspo1 protein (20 ng/ml) or Wnt3A CM (1%) alone had no ef-
fect on ALP activity in primary mouse osteoblasts, treatment
of primary mouse osteoblasts with recombinant Rspo1 protein
plus Wnt3A CM resulted in a signiﬁcantly increase of ALP
activity (Fig. 5B). Moreover, the expression of OCN was also
signiﬁcantly increased after the cells were treated with Rspo1
plus Wnt3A (Fig. 5C).
Recent studies have demonstrated that OPG is a direct tar-
get gene of Wnt/b-catenin signaling in osteoblasts [5,7]. We
then examined OPG expression in C2C12 cells after Rspo1
treatment. We found that Wnt3A, but not Wnt5A, induced
OPG expression in C2C12 cells (Fig. 6A), and that the eﬀect
of Wnt3A on OPG expression was dose dependent (Fig. 6B).
Similar to ALP production, Rspo1 alone was unable to induce
OPG expression in C2C12 cells even at the concentration as
high as 1250 ng/ml (Fig. 6C) or 25% of Rspo1 CM (Fig. 6B).
However, Rspo1 at low concentrations synergized with Wnt3A
to induce OPG expression in C2C12 cells. Treatment of C2C12
cells with 10 ng/ml of recombinant Rspo1 protein plus 0.2% or
1% of Wnt3A CM for 2 days induced them to produce OPG
W. Lu et al. / FEBS Letters 582 (2008) 643–650 647(Fig. 6E and F). Similarly, C2C12 cells expressed OPG after
the treatment with 1–4% of Rspo1 CM plus 1% of Wnt3A
CM for 2 days (Fig. 6G).
Dkk1 is a potent Wnt/b-catenin antagonist which binds the
low density lipoprotein receptor-related protein 6 (LRP6) with
a high aﬃnity [21–23]. LRP6 is an essential co-receptor for the
Wnt/b-catenin signaling pathway. LRP6 phosphorylation is
critical for the activation of Wnt/b-catenin signaling [20]. Very
recently, it has been reported that Rspo1 induces LRP6 phos-
phorylation in MEF cells [18]. LRP6 is expressed in C2C12
cells, while LRP5 expression is undetectable by RT-PCR (data
not shown). To test whether Dkk1 aﬀects Rspo1-induced Wnt/
b-catenin signaling activation in C2C12 cells, we treated the
cells with either Rspo1, Wnt3A CM, or Rspo1 plus Wnt3A
CM in the presence or absence of Dkk1 and examined the lev-
els of LRP6 phosphorylation and cytosolic b-catenin stabiliza-
tion in C2C12 cells. It was found that Rspo1 (10 ng/ml)
synergized with Wnt3A CM (1%) to induce LRP6 phosphory-
lation in C2C12 cells, and that Dkk1 was able to block LRP6Fig. 5. Rspo1 acts synergistically with Wnt3A to induce primary mouse
osteoblasts and C2C12 cells. Rspo1 mRNA was examined in total RNA from
reverse transcription (RT) as described in Section 2. (B) Rspo1 acts syne
osteoblasts in 24-well plates were incubated with recombinant Rspo1 protein (
the media were changed every 2 days. At the end of treatment, cells were harv
the average of triple determinations with the S.D. indicated by error bars. **P
with Rspo1, Wnt3A CM, or L cell control CM alone. (C) Rspo1 acts syn
osteoblasts in 6-well plates were incubated with recombinant Rspo1 protein (2
the media were changed every 2 days. At the end of treatment, cells were harv
values are the average of triple determinations with the S.D. indicated by err
incubated with L cell control CM alone.phosphorylation and cytosolic free b-catenin accumulation in-
duced by Rspo1, Wnt3A CM, or Rspo1 plus Wnt3A CM
(Fig. 7A). Moreover, Dkk1 treatment signiﬁcantly reduced
ALP production (Fig. 7B) and completely abolished OPG
expression induced by Rspo1 plus Wnt3A (Fig. 7C).4. Discussion
In recent years, Wnt/b-catenin signaling has been shown to
play a substantial role in the control of bone development
and remodeling. Previous study has identiﬁed Rspo1 as a po-
tent and speciﬁc mitogen for the gastrointestinal epithelium
and demonstrated a potential therapeutic application for this
protein in mouse models of cancer therapy-induced mucositis
[9,10]. Rspo1 is expressed in primary mouse osteoblasts and
C2C12 cells as examined by RT-PCR. We demonstrated herein
for the ﬁrst time that human Rspo1 synergized strongly with
Wnt3A to induce osteoblasts diﬀerentiation and OPGosteoblast diﬀerentiation. (A) Rspo1 expression in primary mouse
primary mouse osteoblasts and C2C12 cells by PCR with or without
rgistically with Wnt3A to induce ALP production. Primary mouse
20 ng/ml), Wnt3A CM (1%), or Rspo1 plus Wnt3A CM for 6 days, and
ested for ALP activity assay as described in Section 2. All the values are
< 0.01 indicates a signiﬁcant diﬀerence compared with cells incubated
ergistically with Wnt3A to induce OCN expression. Primary mouse
0 ng/ml), Wnt3A CM (1%), or Rspo1 plus Wnt3A CM for 8 days, and
ested and OCN mRNA was determined by real-time RT-PCR. All the
or bars. *P < 0.05 indicates a signiﬁcant diﬀerence compared with cells
Fig. 6. Rspo1 acts synergistically with Wnt3A to promote OPG expression in C2C12 cells. (A) Wnt3A induced OPG expression in C2C12 cells.
C2C12 cells in 6-well plates were incubated with 25% of L cell control CM, Wnt3A CM, or Wnt5A CM for 48 h. The levels of total cellular OPG
were then analyzed by Western blotting. (B) Concentration dependent induction of OPG expression by Wnt3A. C2C12 cells in 6-well plates were
incubated with 0–25% of L cell Wnt3A CM for 48 h. (C,D) Rspo1 alone was unable to induce OPG expression in C2C12 cells. Wnt3A CM (25%) was
served a positive control. In (C), Rspo1 CM was used. In (D), recombinant Rspo1 protein was used. (E-G) Rspo1 acts synergistically with Wnt3A to
induce OPG expression in C2C12 cells. In (E), 10 ng/ml of Rspo1 and 0.2% of Wnt3A CM were used. In (F), 10 ng/ml of Rspo1 and 1% of Wnt3A
CM were used. In (G), 1–4% of Rspo1 CM and 1% of Wnt3A CM were used. All the samples for each Western blotting were also probed with anti-
actin antibody to verify equal loading.
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in bone remodeling.
Wnt and R-spondin share many features in terms of the acti-
vation of Wnt/b-catenin signaling [9,17,18]. In the present
study, we found that both Rspo1 and Wnt3A were able to in-
duce cytosolic free b-catenin stabilization. However, Wnt3A
was more potent than Rspo1 in activation of the Wnt/b-cate-
nin pathway in C2C12 cells. For example, Rspo1 induced cyto-
solic free b-catenin stabilization at low concentrations (10 ng/
ml or 2% of Rspo1 CM), but higher doses of Rspo1 did not
further increase the levels of cytosolic free b-catenin. In addi-
tion, Wnt3A alone, but not Rspo1 alone, was able to signiﬁ-
cantly enhance ALP production and OPG expression in
C2C12 cells. Critically, on the other hand, we also found that
Rspo1 at the concentrations as low as 10–20 ng/ml synergizedstrongly with Wnt3A to activate Wnt/b-catenin signaling, and
to induce osteoblast diﬀerentiation and OPG expression. These
results suggest that Rspo1 may play important roles in regula-
tion of osteoblast diﬀerentiation and osteoclast function at
pathophysiological conditions. With its unique feature in
inducing osteoblast diﬀerentiation and OPG expression with
Wnt proteins at low concentrations, Rpo1 may have a poten-
tial therapeutic application in bone disorders such as osteopo-
rosis.
LRP6 is an essential co-receptor for the Wnt/b-catenin
signaling pathway and is subjected to modulation by many se-
creted proteins [20]. It has been reported that the activation of
Wnt/b-catenin signaling induced by R-spondins was enhanced
by LRP6 co-expression [17,18], and blocked by LRP6 inhibitor
Dkk1 [9,17,18]. Furthermore, Binnerts et al. very recently
Fig. 7. Dkk1 blocked LRP6 phosphorylation, b-catenin stabilization, osteoblastic diﬀerentiation, and OPG expression induced by Rspo1 and
Wnt3A. (A) Dkk1 blocked LRP6 phosphorylation and b-catenin stabilization induced by Rspo1 and Wnt3A. C2C12 cells in 6-well plates were
pretreated with or without Dkk1 (200 ng/ml) for 2 h, and then incubated with Rspo1 (10 ng/ml) and/or Wnt3A CM (1%) for 4 h. The levels of
phosphorylated LRP6, cytosolic free b-catenin and total cellular b-catenin were then analyzed by Western blotting. All the samples for each Western
blotting were also probed with anti-actin antibody to verify equal loading. (B) Dkk1 blocked osteoblastic diﬀerentiation induced by Rspo1 and
Wnt3A. C2C12 cells in 12-well plates were incubated with Rspo1 (10 ng/ml) and/or Wnt3A (0.2% or 1%) in the presence or absence of Dkk1 (200 ng/
ml or 400 ng/ml). Cells were harvested 48 h later for assay for ALP activity. All the values are the average of triple determinations with the S.D.
indicated by error bars. **P < 0.01 verse cells treated with Rspo1 plus Wnt3A. (C) Dkk1 blocked OPG expression induced by Rspo1 and Wnt3A.
C2C12 cells in 6-well plates were incubated with Rspo1 (10 ng/ml) and/or Wnt3A (0.2% or 1%) in the presence or absence of Dkk1 (200 ng/ml) for
48 h. The levels of total cellular OPG were analyzed by Western blotting. All the samples for each Western blotting were also probed with anti-actin
antibody to verify equal loading.
W. Lu et al. / FEBS Letters 582 (2008) 643–650 649reported that Rspo1 regulates Wnt signaling by modulating
levels of LRP6 on the cell surface, through inhibition of
Dkk1-dependent internalization of LRP6 [24]. Although
LRP6 is critical for R-spondin action, the direct interaction be-
tween LRP6 and R-spondins remains controversial [17,18,24].
Dkk1 binds LRP6 with a high aﬃnity, and is a potent Wnt/b-
catenin inhibitor [21–23]. In the present study, we demon-
strated that Dkk1 blocked LRP6 phosphorylation, cytosolic
free b-catenin stabilization, ALP production, and OPG expres-
sion induced by Rspo1 and/or Wnt3A in C2C12 cells, suggest-
ing that Rspo1 function is dependent on LRP6 activity. In the
future, we should dissect precise mechanisms by which Rspo1
at low concentrations cooperates with Wnt to induce Wnt/b-
catenin signaling, osteoblast diﬀerentiation, and OPG expres-
sion.
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